SCHEMBL5373346

SCHEMBL5373346

O=C1Nc2ccc(I)cc2C1=Cc1ccc[nH]1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 12/20 0.71
PDGFRB P09619 5/20 0.71
RET P07949 4/20 0.71
KDR P35968 4/20 0.71
FLT3 P36888 3/20 0.71
ALK Q9UM73 2/20 0.71
FLT1 P17948 2/20 0.71
PDGFRA P16234 1/20 0.71
TLK2 Q86UE8 6/20 0.68
JAK3 P52333 5/20 0.68
SYK P43405 1/20 0.68
ATM Q13315 1/20 0.68
CHEK1 O14757 1/20 0.68
AURKA O14965 1/20 0.68
DAPK3 O43293 1/20 0.68
PRKD3 O94806 1/20 0.68
MAP4K4 O95819 1/20 0.68
NTRK1 P04629 1/20 0.68
LCK P06239 1/20 0.68
FYN P06241 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6965867 1.00 PDPK1 (0.71) PDPK1PDGFRBRETKDRFLT3
SCHEMBL5728408 0.83 PDPK1 (0.76) PDPK1PDGFRBRETKDRFLT3
SCHEMBL18053 0.83 PDPK1 (1.00) PDPK1PDGFRBRETKDRFLT3
SCHEMBL5727977 0.83 PDPK1 (1.00) PDPK1PDGFRBRETKDRFLT3
SCHEMBL13081202 0.83 PDGFRB (0.80) PDPK1PDGFRBRETKDRFLT3
SCHEMBL5727973 0.83 PDPK1 (1.00) PDPK1PDGFRBRETKDRFLT3
SCHEMBL3912682 0.83 PDGFRB (1.00) PDPK1PDGFRBRETKDRFLT3
SCHEMBL18054 0.83 PDPK1 (1.00) PDPK1PDGFRBRETKDRFLT3
SCHEMBL19691 0.83 PDPK1 (1.00) PDPK1PDGFRBRETKDRFLT3
SCHEMBL19692 0.83 PDPK1 (1.00) PDPK1PDGFRBRETKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1149092-B1 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES HOFFMANN LA ROCHE (CH) 2003-10-29 EP disclosed
CN-1331689-A 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles HOFFMANN LA ROCHE (CH) 2002-01-16 CN disclosed
US-6313310-B1 JUN N-TERMINAL KINASE (JNK) ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC ARTHRITIS AND NEURO-DEGENERATIVE DISEASE TREATMENT HOFFMANN-LA ROCHE INC. 2001-11-06 US disclosed
EP-1149092-A2 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP disclosed
WO-2000035906-A2 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PDPK1 31/4885PDGFRB 52/4885RET 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.